Is KLRA or ARTV more profitable?

Kailera Therapeutics' return on equity of 0.00% beat Artiva Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Kailera Therapeutics N/A N/A N/A Artiva Biotherapeutics N/A -53.86% -48.16%

Does the media prefer KLRA or ARTV?

In the previous week, Artiva Biotherapeutics had 1 more articles in the media than Kailera Therapeutics. MarketBeat recorded 7 mentions for Artiva Biotherapeutics and 6 mentions for Kailera Therapeutics. Artiva Biotherapeutics' average media sentiment score of 1.14 beat Kailera Therapeutics' score of 0.14 indicating that Artiva Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kailera Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Artiva Biotherapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ARTV or MESO more profitable?

Mesoblast's return on equity of 0.00% beat Artiva Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Artiva Biotherapeutics N/A -53.86% -48.16% Mesoblast N/A N/A N/A

Does the media refer more to ARTV or MESO?

In the previous week, Mesoblast had 2 more articles in the media than Artiva Biotherapeutics. MarketBeat recorded 9 mentions for Mesoblast and 7 mentions for Artiva Biotherapeutics. Artiva Biotherapeutics' average media sentiment score of 1.14 beat Mesoblast's score of 0.33 indicating that Artiva Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artiva Biotherapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mesoblast 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ARTV or AUPH?

In the previous week, Aurinia Pharmaceuticals had 3 more articles in the media than Artiva Biotherapeutics. MarketBeat recorded 10 mentions for Aurinia Pharmaceuticals and 7 mentions for Artiva Biotherapeutics. Aurinia Pharmaceuticals' average media sentiment score of 1.48 beat Artiva Biotherapeutics' score of 1.14 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artiva Biotherapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aurinia Pharmaceuticals 9 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VCEL or ARTV?

In the previous week, Artiva Biotherapeutics had 1 more articles in the media than Vericel. MarketBeat recorded 7 mentions for Artiva Biotherapeutics and 6 mentions for Vericel. Vericel's average media sentiment score of 1.79 beat Artiva Biotherapeutics' score of 1.14 indicating that Vericel is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vericel 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Artiva Biotherapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ZBIO or ARTV more profitable?

Artiva Biotherapeutics' return on equity of -53.86% beat Zenas BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets Zenas BioPharma N/A -122.45% -58.04% Artiva Biotherapeutics N/A -53.86% -48.16%

Does the media prefer ZBIO or ARTV?

In the previous week, Artiva Biotherapeutics had 4 more articles in the media than Zenas BioPharma. MarketBeat recorded 7 mentions for Artiva Biotherapeutics and 3 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 1.28 beat Artiva Biotherapeutics' score of 1.14 indicating that Zenas BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zenas BioPharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Artiva Biotherapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Artiva Biotherapeutics (ARTV) Competitors

$11.09 -0.85 (-7.12%)

As of 08/28/2026 04:00 PM Eastern

Compare

ARTV vs. KLRA, MESO, AUPH, VCEL, and ZBIO

Should you buy Artiva Biotherapeutics stock or one of its competitors? Artiva Biotherapeutics's main competitors and comparable companies include Kailera Therapeutics (KLRA), Mesoblast (MESO), Aurinia Pharmaceuticals (AUPH), Vericel (VCEL), and Zenas BioPharma (ZBIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Artiva Biotherapeutics compare to Kailera Therapeutics?

Kailera Therapeutics (NASDAQ:KLRA) and Artiva Biotherapeutics (NASDAQ:ARTV) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

Kailera Therapeutics currently has a consensus target price of $42.75, suggesting a potential upside of 163.73%. Artiva Biotherapeutics has a consensus target price of $39.00, suggesting a potential upside of 251.67%. Given Artiva Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Artiva Biotherapeutics is more favorable than Kailera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kailera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Artiva Biotherapeutics has higher revenue and earnings than Kailera Therapeutics. Artiva Biotherapeutics is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kailera Therapeutics	N/A	N/A	-$148.96M	-$3.65 thousand	N/A
Artiva Biotherapeutics	$250K	2,168.76	-$83.86M	-$3.30	N/A

In the previous week, Artiva Biotherapeutics had 1 more articles in the media than Kailera Therapeutics. MarketBeat recorded 7 mentions for Artiva Biotherapeutics and 6 mentions for Kailera Therapeutics. Artiva Biotherapeutics' average media sentiment score of 1.14 beat Kailera Therapeutics' score of 0.14 indicating that Artiva Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kailera Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Artiva Biotherapeutics	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kailera Therapeutics' return on equity of 0.00% beat Artiva Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kailera Therapeutics	N/A	N/A	N/A
Artiva Biotherapeutics	N/A	-53.86%	-48.16%

Summary

Artiva Biotherapeutics beats Kailera Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Artiva Biotherapeutics compare to Mesoblast?

Artiva Biotherapeutics (NASDAQ:ARTV) and Mesoblast (NASDAQ:MESO) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, dividends and analyst recommendations.

In the previous week, Mesoblast had 2 more articles in the media than Artiva Biotherapeutics. MarketBeat recorded 9 mentions for Mesoblast and 7 mentions for Artiva Biotherapeutics. Artiva Biotherapeutics' average media sentiment score of 1.14 beat Mesoblast's score of 0.33 indicating that Artiva Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artiva Biotherapeutics	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mesoblast	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Mesoblast has higher revenue and earnings than Artiva Biotherapeutics. Mesoblast is trading at a lower price-to-earnings ratio than Artiva Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artiva Biotherapeutics	$250K	2,168.76	-$83.86M	-$3.30	N/A
Mesoblast	$120.25M	18.84	-$57.50M	-$0.28	N/A

Artiva Biotherapeutics has a beta of 2.16, meaning that its share price is 116% more volatile than the broader market. Comparatively, Mesoblast has a beta of 2.08, meaning that its share price is 108% more volatile than the broader market.

Mesoblast's return on equity of 0.00% beat Artiva Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artiva Biotherapeutics	N/A	-53.86%	-48.16%
Mesoblast	N/A	N/A	N/A

Artiva Biotherapeutics presently has a consensus price target of $39.00, indicating a potential upside of 251.67%. Mesoblast has a consensus price target of $39.00, indicating a potential upside of 123.62%. Given Artiva Biotherapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Artiva Biotherapeutics is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Mesoblast	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

1.4% of Mesoblast shares are owned by institutional investors. 1.8% of Artiva Biotherapeutics shares are owned by company insiders. Comparatively, 18.8% of Mesoblast shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Artiva Biotherapeutics and Mesoblast tied by winning 8 of the 16 factors compared between the two stocks.

How does Artiva Biotherapeutics compare to Aurinia Pharmaceuticals?

Artiva Biotherapeutics (NASDAQ:ARTV) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

Artiva Biotherapeutics presently has a consensus price target of $39.00, suggesting a potential upside of 251.67%. Aurinia Pharmaceuticals has a consensus price target of $17.67, suggesting a potential upside of 8.45%. Given Artiva Biotherapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Artiva Biotherapeutics is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Aurinia Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.67

Aurinia Pharmaceuticals has higher revenue and earnings than Artiva Biotherapeutics. Artiva Biotherapeutics is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artiva Biotherapeutics	$250K	2,168.76	-$83.86M	-$3.30	N/A
Aurinia Pharmaceuticals	$283.05M	7.66	$287.20M	$2.29	7.11

In the previous week, Aurinia Pharmaceuticals had 3 more articles in the media than Artiva Biotherapeutics. MarketBeat recorded 10 mentions for Aurinia Pharmaceuticals and 7 mentions for Artiva Biotherapeutics. Aurinia Pharmaceuticals' average media sentiment score of 1.48 beat Artiva Biotherapeutics' score of 1.14 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artiva Biotherapeutics	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aurinia Pharmaceuticals	9 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. 1.8% of Artiva Biotherapeutics shares are owned by insiders. Comparatively, 10.4% of Aurinia Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Artiva Biotherapeutics has a beta of 2.16, indicating that its share price is 116% more volatile than the broader market. Comparatively, Aurinia Pharmaceuticals has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market.

Aurinia Pharmaceuticals has a net margin of 100.84% compared to Artiva Biotherapeutics' net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 26.11% beat Artiva Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artiva Biotherapeutics	N/A	-53.86%	-48.16%
Aurinia Pharmaceuticals	100.84%	26.11%	19.89%

Summary

Aurinia Pharmaceuticals beats Artiva Biotherapeutics on 11 of the 16 factors compared between the two stocks.

How does Artiva Biotherapeutics compare to Vericel?

Vericel (NASDAQ:VCEL) and Artiva Biotherapeutics (NASDAQ:ARTV) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, dividends and earnings.

Vericel currently has a consensus price target of $58.40, suggesting a potential upside of 42.61%. Artiva Biotherapeutics has a consensus price target of $39.00, suggesting a potential upside of 251.67%. Given Artiva Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Artiva Biotherapeutics is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Vericel has higher revenue and earnings than Artiva Biotherapeutics. Artiva Biotherapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$276.26M	7.59	$16.52M	$0.47	87.13
Artiva Biotherapeutics	$250K	2,168.76	-$83.86M	-$3.30	N/A

Vericel has a net margin of 7.91% compared to Artiva Biotherapeutics' net margin of 0.00%. Vericel's return on equity of 6.91% beat Artiva Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vericel	7.91%	6.91%	5.02%
Artiva Biotherapeutics	N/A	-53.86%	-48.16%

Vericel has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market. Comparatively, Artiva Biotherapeutics has a beta of 2.16, meaning that its share price is 116% more volatile than the broader market.

In the previous week, Artiva Biotherapeutics had 1 more articles in the media than Vericel. MarketBeat recorded 7 mentions for Artiva Biotherapeutics and 6 mentions for Vericel. Vericel's average media sentiment score of 1.79 beat Artiva Biotherapeutics' score of 1.14 indicating that Vericel is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vericel	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Artiva Biotherapeutics	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Vericel beats Artiva Biotherapeutics on 8 of the 14 factors compared between the two stocks.

How does Artiva Biotherapeutics compare to Zenas BioPharma?

Zenas BioPharma (NASDAQ:ZBIO) and Artiva Biotherapeutics (NASDAQ:ARTV) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, dividends and earnings.

Artiva Biotherapeutics' return on equity of -53.86% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-122.45%	-58.04%
Artiva Biotherapeutics	N/A	-53.86%	-48.16%

Artiva Biotherapeutics has lower revenue, but higher earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Artiva Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	$10M	203.82	-$377.74M	-$8.99	N/A
Artiva Biotherapeutics	$250K	2,168.76	-$83.86M	-$3.30	N/A

In the previous week, Artiva Biotherapeutics had 4 more articles in the media than Zenas BioPharma. MarketBeat recorded 7 mentions for Artiva Biotherapeutics and 3 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 1.28 beat Artiva Biotherapeutics' score of 1.14 indicating that Zenas BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zenas BioPharma	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Artiva Biotherapeutics	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zenas BioPharma currently has a consensus price target of $45.71, suggesting a potential upside of 46.19%. Artiva Biotherapeutics has a consensus price target of $39.00, suggesting a potential upside of 251.67%. Given Artiva Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Artiva Biotherapeutics is more favorable than Zenas BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Zenas BioPharma has a beta of -1.03, meaning that its share price is 203% less volatile than the broader market. Comparatively, Artiva Biotherapeutics has a beta of 2.16, meaning that its share price is 116% more volatile than the broader market.

Summary

Artiva Biotherapeutics beats Zenas BioPharma on 11 of the 14 factors compared between the two stocks.

Get Artiva Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARTV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARTV vs. The Competition

Export

Metric	Artiva Biotherapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$542.19M	$3.93B	$7.21B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-3.36	11.62	273.16	25.42
Price / Sales	2,168.76	1,369.80	630.81	94.42
Price / Cash	N/A	44.06	28.74	36.03
Price / Book	2.48	16.92	11.08	6.36
Net Income	-$83.86M	-$22.74M	$3.48B	$349.79M
7 Day Performance	1.46%	-0.31%	0.13%	-0.80%
1 Month Performance	6.33%	9.80%	7.08%	4.13%
1 Year Performance	252.06%	55.66%	24.67%	15.17%

Artiva Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARTV Artiva Biotherapeutics	3.1431 of 5 stars	$11.09 -7.1%	$39.00 +251.7%	+252.1%	$542.19M	$250K	N/A	81	Positive News
KLRA Kailera Therapeutics	2.5321 of 5 stars	$17.75 +7.3%	$42.75 +140.8%	N/A	$2.30B	N/A	N/A	145
MESO Mesoblast	2.4427 of 5 stars	$17.19 +3.3%	N/A	+26.1%	$2.23B	$17.20M	N/A	80	Upcoming Earnings Analyst Forecast
AUPH Aurinia Pharmaceuticals	3.6939 of 5 stars	$16.75 +1.1%	$17.67 +5.5%	+35.9%	$2.23B	$283.05M	7.31	300	News Coverage Analyst Upgrade
VCEL Vericel	3.7744 of 5 stars	$43.22 +2.2%	$58.40 +35.1%	+12.6%	$2.21B	$306.30M	91.96	300	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARTV) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Artiva Biotherapeutics (ARTV) Competitors

ARTV vs. KLRA, MESO, AUPH, VCEL, and ZBIO

How does Artiva Biotherapeutics compare to Kailera Therapeutics?

Summary

How does Artiva Biotherapeutics compare to Mesoblast?

Summary

How does Artiva Biotherapeutics compare to Aurinia Pharmaceuticals?

Summary

How does Artiva Biotherapeutics compare to Vericel?

Summary

How does Artiva Biotherapeutics compare to Zenas BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARTV vs. The Competition

Artiva Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Artiva Biotherapeutics (ARTV) Competitors

ARTV vs. KLRA, MESO, AUPH, VCEL, and ZBIO

How does Artiva Biotherapeutics compare to Kailera Therapeutics?

Do analysts recommend KLRA or ARTV?

Which has preferable earnings & valuation, KLRA or ARTV?

Does the media prefer KLRA or ARTV?

Is KLRA or ARTV more profitable?

Summary

How does Artiva Biotherapeutics compare to Mesoblast?

Does the media refer more to ARTV or MESO?

Which has stronger valuation & earnings, ARTV or MESO?

Which has more risk and volatility, ARTV or MESO?

Is ARTV or MESO more profitable?

Do analysts recommend ARTV or MESO?

Do insiders and institutionals have more ownership in ARTV or MESO?

Summary

How does Artiva Biotherapeutics compare to Aurinia Pharmaceuticals?

Do analysts rate ARTV or AUPH?

Which has stronger earnings and valuation, ARTV or AUPH?

Does the media favor ARTV or AUPH?

Do institutionals and insiders hold more shares of ARTV or AUPH?

Which has more risk and volatility, ARTV or AUPH?

Is ARTV or AUPH more profitable?

Summary

How does Artiva Biotherapeutics compare to Vericel?

Do analysts rate VCEL or ARTV?

Which has preferable valuation & earnings, VCEL or ARTV?

Is VCEL or ARTV more profitable?

Which has more risk & volatility, VCEL or ARTV?

Does the media prefer VCEL or ARTV?

Summary

How does Artiva Biotherapeutics compare to Zenas BioPharma?

Is ZBIO or ARTV more profitable?

Which has preferable valuation & earnings, ZBIO or ARTV?

Does the media prefer ZBIO or ARTV?

Do analysts rate ZBIO or ARTV?

Which has more risk & volatility, ZBIO or ARTV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARTV vs. The Competition

Artiva Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools